Evidence map›Paper›PMID 33758378›Full record

ArticleNature reviews. Clinical oncology2021

Author Correction: COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials.

Aakash Desai, Justin F Gainor, Aparna Hegde, Alison M Schram, Giuseppe Curigliano, Sumanta Pal, Stephen V Liu, Balazs Halmos, Roman Groisberg, Enrique Grande and 15 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature reviews. Clinical oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

25 authors.

Aakash DesaiDivision of Medical Oncology, Mayo Clinic College of Medicine, Rochester, MN, USA.
Justin F GainorDepartment of Medicine, Massachusetts General Hospital, Boston, MA, USA.
Aparna HegdeDepartment of Hematology and Oncology, O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL, USA.
Alison M SchramMemorial Sloan Kettering Cancer Center, New York, NY, USA.
Giuseppe CuriglianoDepartment of Oncology and Hemato- Oncology, University of Milan and European Institute of Oncology, IRCCS, Milan, Italy.ORCID http://orcid.org/0000-0003-1781-2518
Sumanta PalDepartment of Medical Oncology, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
Stephen V LiuDepartment of Developmental Therapeutics, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA.
Balazs HalmosDepartment of Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, The Bronx, NY, USA.
Roman GroisbergDepartment of Melanoma/Sarcoma Medical Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.ORCID http://orcid.org/0000-0001-8970-7675
Enrique GrandeDepartment of Medical Oncology, MD Anderson Cancer Center Madrid, Madrid, Spain.
Tomislav DragovichDepartment of Hematology/Oncology, MD Anderson Banner Cancer Center, Gilbert, AZ, USA.
Marc MatranaPrecision Cancer Therapies (Phase I) Research Program, Experimental Therapeutics, Ochsner, New Orleans, LA, USA.
Neeraj AgarwalDivision of Oncology, Department of Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
Sant ChawlaSarcoma Oncology Center, Santa Monia, CA, USA.
Shumei KatoCenter for Personalized Cancer Therapy, Moores Cancer Center, University of California San Diego, La Jolla, CA, USA.
Gilberto MorganDepartment of Oncology, Skåne University Hospital, Lund, Sweden.
Pashtoon M KasiDivision of Hematology, Oncology and Blood and Marrow Transplantation, Department of Medicine, University of Iowa, Iowa City, IA, USA.ORCID http://orcid.org/0000-0002-5169-7085
Benjamin SolomonDepartment of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Herbert H LoongDepartment of Clinical Oncology, State Key Laboratory of Translational Oncology, The Chinese University of Hong Kong, Hong Kong SAR, China.
Haeseong ParkDivision of Oncology, Department of Medicine, Washington University in St. Louis, St Louis, MO, USA.
Toni K ChoueiriDepartment of Medical Oncology, Dana- Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0002-9201-3217
Ishwaria M SubbiahDepartment of Palliative, Rehabilitation & Integrative Medicine, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-0758-7911
Naveen PemmarajuDepartment of Leukemia, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Vivek SubbiahDepartment of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA. vsubbiah@mdanderson.org.ORCID http://orcid.org/0000-0002-6064-6837
COVID19 and Cancer Clinical Trials Working Group

Funding

Viral VectorP30CA086862 · NCI · UNIVERSITY OF IOWA · PI Christopher K Laubenthal · 2000 to 2026
$70.0M
Montefiore Academic Community NCORP ProgramUG1CA189859 · NCI · MONTEFIORE MEDICAL CENTER (BRONX, NY) · PI Balazs Halmos, Della Makower · 2014 to 2026
$10.8M
NCI NIH HHS UG1 CA189859
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID33758378
PMCPMC7985918

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.